{"Title": ["Is Amgen Stock a Buy?", "Is Now Still a Good Time To Buy Amgen?", "Here's Why Cytokinetics Is Skyrocketing 24.5% Today", "Monday's ETF Movers: XBI, KRE", "BUZZ-U.S. STOCKS ON THE MOVE-Banks, Boeing, Uber, Disney", "BUZZ-U.S. STOCKS ON THE MOVE-Banks, Uber, Roku, Sorrento Therapeutics", "Amgen:FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure", "Cytokinetics Inc (CYTK) Q1 2020 Earnings Call Transcript", "Is Amgen Stock a Buy?", "3 Monster Growth Stocks With Still Plenty of Gas in the Tank", "Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript", "Stock To Watch: One Down, One To Go For Cytokinetics (CYTK)", "5 \u201cStrong Buy\u201d Biotech Stocks With More Than 80% Upside", "Here's Why Cytokinetics Stock Tanked on Thursday", "Cytokinetics Inc (CYTK) Q3 2019 Earnings Call Transcript", "Cytokinetics Inc (CYTK) Q2 2019 Earnings Call Transcript", "3 Biotech Stocks With Plenty of Upside in the Pipeline", "Analysts Anticipate 16% Gains Ahead For IJS", "Cytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript", "Here's Why Cytokinetics Stock Jumped Today", "Amgen Starts Phase III Enrollment for Heart Failure Drug", "Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript", "Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates", "The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna", "Notable Monday Option Activity: WDAY, CYTK, ARAY", "5 Tiny Biotech Stocks With Superb Growth Potential", "Cytokinetics Sees Hammer Chart Pattern: Time to Buy?", "Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates", "Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide", "Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For $15/Share", "Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2/18/2018", "Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know", "Thursday's ETF Movers: XBI, ILF", "Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks", "Pre-Market Most Active for Nov 21, 2017 : QD, XNET, URBN, SIG, CYTK, LOW, TVIX, AKS, DLTR, BABA, MT, MU", "Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?", "Noteworthy Wednesday Option Activity: SGEN, CYTK, WRD", "Implied Volatility Surging for Cytokinetics (CYTK) Stock Options", "Notable Monday Option Activity: GS, CYTK, CMPR", "Paratek Pharmaceuticals Set To Explode As The Holy Grail Of Antibiotics Omadacycline Nears FDA Approval", "New Strong Sell Stocks for May 4th", "After Hours Most Active for Apr 21, 2017 : SBGL, CBL, BAC, QQQ, MS^K, VNQI, PEY, FB, CYTK, TRIP, NYCB^A, GE", "Why Cytokinetics, Inc. Jumped Higher Today", "Wednesday's ETF Movers: XBI, XOP", "ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y", "Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up", "Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%", "Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock", "Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI", "Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)", "5 Profitability Stocks to Make the Most of Trump Bump", "3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock", "Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife", "Cytokinetics (CYTK): An Off-the-Radar Potential Winner", "What Took So Long?", "Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4", "Cytokinetics (CYTK): Strong Industry, Solid Earnings Estimate Revisions", "3 Small Biotech Stocks That Big Biotechs Like", "Surging Earnings Estimates Signal Good News for Cytokinetics (CYTK)", "Spinal Muscular Atrophy in Focus as Biogen, IONS Shoot Up on Data", "Cytokinetics (CYTK): An Off-the-Radar Potential Winner", "Cytokinetics (CYTK) Worth Watching: Stock Surges 10.3%", "Health Care Sector Update for 10/28/2016: CYTK,ATRC,OPXA", "5 Profitable Stocks to Buy for Great Returns", "Health Care Sector Update for 09/01/2016: CASC,CYNA,CTH.TO,CYTK", "Noteworthy Thursday Option Activity: SGMS, CYTK, GCO", "Why Cytokinetics, Inc. Got Hammered Today", "Energy Sector Update for 09/01/2016: NURO,CYNA,CTH.TO,CYTK", "Why You Shouldn't Bet Against Cytokinetics (CYTK) Stock", "Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled", "Cytokinetics (CYTK) Shares March Higher, Can It Continue?", "Noteworthy Friday Option Activity: CNP, CAT, CYTK", "What's in Store for TransUnion's (TRU) Q4 Earnings?", "Baxalta (BXLT) to Report Q4 Earnings: A Surprise in Store?", "Should You Buy Cytokinetics (CYTK) Ahead of Earnings?", "Can Zoetis (ZTS) Keep the Earnings Streak Alive in Q4?", "Mylan (MYL) to Report Q4 Earnings: What's in the Cards?", "3 Biotech Stocks to Turn the Tide This Earnings Season", "Regeneron (REGN) to Report Q4 Earnings: What's in Store?", "Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session", "Top-Rated Stock Picks and Most-Read Stories at Nasdaq.com: January 24 - 30", "Can Perrigo (PRGO) Beat Q4 Earnings on Generic Sales?", "Is Alexion (ALXN) Likely to Disappoint this Earnings Season?", "GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?", "What's in Store for Nivalis (NVLS) this Earnings Season?", "Can Gilead (GILD) Keep the Earnings Streak Alive in Q4?", "ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?", "Will AmerisourceBergen's (ABC) Q1 Earnings Disappoint?", "Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb", "4 Biotech Stocks Looking Good this Earnings Season", "How Cytokinetics (CYTK) Stock Stands Out in a Strong Industry", "New Strong Buy Stocks for December 15th", "The 3 Most Important Drugs in Amgen's Pipeline", "Cytokinetics (CYTK) Looks Good: Stock Moves 8.8% Higher", "Celgene (CELG) to Report Q4 Earnings: What to Expect?", "Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?", "The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb", "4 Biotech Stocks Looking Good this Earnings Season", "How Cytokinetics (CYTK) Stock Stands Out in a Strong Industry", "New Strong Buy Stocks for December 15th", "Intercept (ICPT) Posts Narrower-than-Expected Loss in Q3", "5 Stocks Rocketing to New Highs", "Can Cytokinetics (CYTK) Run Higher on Strong Earnings Estimate Revisions?", "Mid-Afternoon Market Update: Dow Surges 150 Points; Lendingtree Shares Slide", "Monday Sector Leaders: Biotechnology, Drugs", "Cytokinetics (CYTK) Jumps: Stock Adds 16.6% in Session", "Noteworthy Thursday Option Activity: MNKD, VTL, CYTK", "Earnings Estimates Moving Higher for Cytokinetics (CYTK): Time to Buy?", "New Strong Sell Stocks for July 24th - Tale of the Tape", "Will Biogen (BIIB) Surprise in 2Q Despite Tecfidera Issues? - Analyst Blog", "Mid-Day Market Update: Dyax Jumps On Acquisition News; Endurance International Shares Dip", "Cytokinetics (CYTK) Jumps: Stock Adds 6.8% in Session - Tale of the Tape", "Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog", "Mid-Day Market Update: Vince Holding Declines After CEO Resignation; Natural Health Trends Shares Surge", "Mid-Morning Market Update: Markets Rise; JPMorgan Earnings Beat Views", "Health Care Sector Update for 06/19/2015: ACHC, BMRN, CYTK", "Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog", "Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog", "Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog", "Cytokinetics (CYTK) Jumps: Stock Adds 6.8% in Session - Tale of the Tape", "Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog", "Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog", "AstraZeneca's Onglyza Briefing Documents Raise Concern - Analyst Blog", "Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog", "Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog", "Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog", "The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog", "Oncolytics' Reolysin Filed for Gastric Cancer Orphan Status - Analyst Blog", "Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog", "Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog", "Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog", "Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog", "The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog", "Oncolytics' Reolysin Filed for Gastric Cancer Orphan Status - Analyst Blog", "Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog", "Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog", "Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog", "Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog", "The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog", "Oncolytics' Reolysin Filed for Gastric Cancer Orphan Status - Analyst Blog", "Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog", "Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog", "Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog", "Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog", "The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog", "Oncolytics' Reolysin Filed for Gastric Cancer Orphan Status - Analyst Blog", "Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog", "Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog", "Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog", "Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog", "Dyax's Hereditary Angioedema Drug Meets Primary Endpoint - Analyst Blog", "Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog", "Horizon Pharma to Buy Hyperion Therapeutics for $1.1B - Analyst Blog", "Intrexon-Merck KGaA Team Up for CAR-T Cancer Therapies - Analyst Blog", "Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog", "Heat Biologics Posts Wider Loss Y/Y, Focus on Pipeline - Analyst Blog", "Proteon Up on Positive Long-Term Data on its Candidate - Analyst Blog", "Novo Nordisk to Submit Interim DEVOTE Data to the FDA - Analyst Blog", "Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog", "The Medicines Co.'s 3 Acute Care Drugs Approved in EU - Analyst Blog", "Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog", "Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog", "Oncolytics' Cancer Drug Reolysin Gets Orphan Status in EU - Analyst Blog", "Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog", "Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog", "Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog", "Eli Lilly Partners with Innovent to Develop Oncology Drugs - Analyst Blog", "Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog", "Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog", "Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog", "Oncolytics' Cancer Drug Reolysin Gets Orphan Status in EU - Analyst Blog", "Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog", "Eli Lilly Collaborates with Korean Hanmi Pharmaceutical - Analyst Blog", "Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View - Analyst Blog", "Juno Therapeutics' (JUNO) Q4 Loss Wider than Expected - Analyst Blog", "Celgene Presents Efficacy, Safety Data on Otezla - Analyst Blog", "Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog", "Prothena's PRX002 Positive in Parkinson's Disease Study - Analyst Blog", "Coronado Biosciences Jumps on Agreement with NeuPharma - Analyst Blog", "Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog", "Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog", "AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog", "Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog", "Vertex's Kalydeco Gets FDA Nod for Additional Indication - Analyst Blog", "Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog", "Lexicon-Ipsen Agreement Expanded to Include Canada - Analyst Blog", "Nektar's Breast Cancer Candidate Fails in BEACON Study - Analyst Blog", "Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog", "Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog", "AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog", "Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog", "Merck's Sugammadex Faces Setback, FDA Delays Meeting - Analyst Blog", "Alnylam Announces Positive Data from Natural History Study - Analyst Blog", "Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog", "Synta's Q4 Loss Narrows Y/Y, Focus on Lung Cancer Drug - Analyst Blog", "Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog", "XOMA Reports Narrower Y/Y Loss in Q4, Misses on Revs - Analyst Blog", "SciClone (SCLN) Beats on Q4 Earnings, Gives 2015 Outlook - Analyst Blog", "Actelion's Uptravi Shows Long-term Benefit in GRIPHON - Analyst Blog", "Emergent BioSolutions Lags Earnings, Cancels 2015 View - Analyst Blog", "TG Therapeutics-Coronado Sign Up Immuno-Oncology Deal - Analyst Blog", "Bristol-Myers Oncology Drug Opdivo Label Expanded in U.S. - Analyst Blog", "Shire Submits NDA for Dry Eye Disease Drug Lifitegrast - Analyst Blog", "Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog", "Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog", "Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog", "Osiris Therapeutics' Q4 Earnings Down Y/Y, Revenues Soar - Analyst Blog", "Emergent BioSolutions Lags Earnings, Cancels 2015 View - Analyst Blog", "TG Therapeutics-Coronado Sign Up Immuno-Oncology Deal - Analyst Blog", "Bristol-Myers Oncology Drug Opdivo Label Expanded in U.S. - Analyst Blog", "Shire Submits NDA for Dry Eye Disease Drug Lifitegrast - Analyst Blog", "Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog", "Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog", "Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog", "Osiris Therapeutics' Q4 Earnings Down Y/Y, Revenues Soar - Analyst Blog", "Bristol-Myers Files for New Indications for Yervoy, Opdivo - Analyst Blog", "QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog", "Endo (ENDP) Beats Q4 Earnings, Announces Divestments - Analyst Blog", "Horizon Pharma Beats on Q4 Earnings, Lifts 2015 Guidance - Analyst Blog", "Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog", "Alexion's Soliris' Label May be Updated upon EC Approval - Analyst Blog", "Amgen's Kyprolis Under EU Review - Analyst Blog", "Amgen-Celimmune Tie Up for Autoimmune Disorder Drug - Analyst Blog", "Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog", "Aegerion's Q4 Loss Narrows Y/Y, Ups Juxtapid Sales View - Analyst Blog", "Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog", "Nektar Therapeutics Incurs Narrower-than-Expected Q4 Loss - Analyst Blog", "MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog", "VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog", "Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog", "Bayer Q4 Net Income Down Y/Y, Provides 2015 Outlook - Analyst Blog", "Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog", "Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog", "Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog", "The Medicines Co. Earnings Down Y/Y, Angiomax Sales Grow - Analyst Blog", "Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog", "Cytokinetics (CYTK) Shows Strength: Stock Moves Up 5% - Tale of the Tape", "Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog", "Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog", "Why Shares of Cytokinetics Incorporated Skyrocketed", "Health Care Sector Update for 02/13/2015:", "Will Cytokinetics (CYTK) Continue to Surge Higher? - Tale of the Tape", "Cytokinetics (CYTK) Looks Good: Stock Soars 16.1% - Tale of the Tape", "Mid-Day Market Update: Meadowbrook Insurance Shares Jump On Acquisition News; Crude Oil Drops Over 2%", "Mid-Afternoon Market Update: U.S. Stocks Turn Red; Tekmira Pharmaceuticals Shares Climb Following Clinical Study Update", "Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog", "Why Cytokinetics Inc. Shares Soared Today", "Cytokinetics, Incorporated (CYTK) Rises: Stock Jumps 12.6% - Tale of the Tape", "Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog", "Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog", "Avanir's Migraine Drug Gets Complete Response Letter - Analyst Blog", "Amgen Ends Gastric Cancer Drug Studies on Safety Review - Analyst Blog", "Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog", "3 Stocks to Buy With Your Bull Market Profits", "Health Care Sector Update for 12/05/2014: CYTK,ATOS,PBMD", "Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9% - Tale of the Tape", "Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog", "Cytokinetics Up on Positive Tirasemtiv Data - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; ImmunoCelluar up 12% on Positive Data on Immunotherapeutic Vaccine", "Sector Update: Healthcare", "Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog", "Late Slump Erodes Healthcare Sector; Cytokinetics Loses Nearly Two-Thirds in Value After ALS Drug Test Lapse", "Integra LifeSciences Tops Q2 Earnings, Revenues, Shares Up - Analyst Blog", "Friday Sector Laggards: Biotechnology, Construction Materials & Machinery Stocks", "Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape", "Mid-Afternoon Market Update: Markets Post a Large Rally as Intuitive Surgical Shares Remain Down", "Mid-Day Market Update: Alcoa Surges On Upbeat Earnings; Intuitive Surgical Shares Slip", "Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog", "Cytokinetics, Incorporated (CYTK) Soars: Stock Up 26% in Session - Tale of the Tape", "Robust Gains for Healthcare Stocks; Cytokinetics Soars After Surprise Q4 Profit, 11-Fold Jump in Revenue", "Sector Update: Healthcare", "Friday Sector Laggards: Biotechnology, Construction Materials & Machinery Stocks", "Cytokinetics, Inc. Enters Oversold Territory - Tale of the Tape", "Amgen/Cytokinetics Drug Misses Primary Endpoint - Analyst Blog", "Amgen to Present Data at ESC - Analyst Blog", "Cytokinetics: Previewing The Release Of Data From The ATOMIC-AHF Trial Of Omecamtiv Mecarbil", "Cytokinetics' Tirasemtiv Data Published - Analyst Blog", "Sector Update: Healthcare", "Sector Update: Healthcare", "Loss Narrows At Idenix in Q2 - Analyst Blog", "Cytokinetics: A Preview Of Key Upcoming Clinical Trial Results", "Amgen - Servier Ink Deal - Analyst Blog", "Cytokinetics' Update on Study - Analyst Blog", "Cytokinetics, Astellas Collaborate - Analyst Blog", "Theravance's Vibativ Expanded in the US - Analyst Blog", "Healthcare Stocks Slightly Higher This Afternoon; Cytokinetics Advances After New Data Find ALS Drug Well-Tolerated", "Patients Dosed in Arena Study - Analyst Blog", "AZN Reports Data on Fostamatinib - Analyst Blog", "Data Presented on Bayer's ATX-101 - Analyst Blog", "Cytokinetics Begins CK-2127107 Study - Analyst Blog", "GHDX to Show Prostate Test Result - Analyst Blog", "Glaxo Eyes Benlysta Label Expansion - Analyst Blog", "QLT Sells PPDS Technology - Analyst Blog", "Market Wrap for Tuesday, June 18: Stocks Rally Ahead of Fed Statement", "Update on Protalix Gaucher Study - Analyst Blog", "AstraZeneca Takes Over AlphaCore - Analyst Blog", "Orphan Status for Insmed's Arikace - Analyst Blog", "BioMarin Files CTA for BMN-190 - Analyst Blog", "ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog", "Elan Sells Off Tysabri Stake - Analyst Blog", "Celgene Reaches 52-Week High - Analyst Blog", "Elan Gets Takeover Clarity - Analyst Blog", "Update on Protalix Gaucher Study - Analyst Blog", "AstraZeneca Takes Over AlphaCore - Analyst Blog", "Gilead's HCV Study to Continue - Analyst Blog", "Bad News for Alexion, Shares Down - Analyst Blog", "Omeros Progresses with OMS824 - Analyst Blog", "Takeda Seeks Japanese Approval - Analyst Blog", "Balanced View on Gilead Sciences - Analyst Blog", "Vivus Opts for Royalty Financing - Analyst Blog", "LabCorp Remains at Neutral - Analyst Blog", "LIFE Explores China's Growth Potential - Analyst Blog", "Affymetrix Inks Deal with UK Biobank - Analyst Blog", "Takeda Files Adcetris in Japan - Analyst Blog", "CHMP Negative on Gentium Candidate - Analyst Blog", "Acorda Reports Data on Epilepsy Drug - Analyst Blog", "Integra's Second Cobalt Chrome Rod - Analyst Blog", "Setback for Idenix Pharma - Analyst Blog", "CHMP Positive on Biogen's Tecfidera - Analyst Blog", "Cytokinetics: Critical Phase IIb Data Is Upcoming In 2013 For Omecamtiv Mecarbil And Tirasemtiv", "CHMP Positive on Ariad's Iclusig - Analyst Blog", "CHMP Still Negative on Isis' Kynamro - Analyst Blog", "Pipeline Setback at BioLineRx - Analyst Blog", "More Protection for Biogen's Tecfidera - Analyst Blog", "FDA Nod for Integra's Extremity Offer - Analyst Blog", "Zimmer Optimistic About New Product - Analyst Blog", "PetMed Reiterated at Outperform - Analyst Blog", "Zimmer Expands Knee Product Offering - Analyst Blog", "Data on BioMarin's BMN-701 - Analyst Blog", "Good News for Nymox's Pipeline - Analyst Blog", "ISIS Presents Promising Data - Analyst Blog", "SGEN Seeks Adcetris Label Expansion - Analyst Blog", "DGX to Launch Dementia Test Panel - Analyst Blog", "NICE News for InterMune - Analyst Blog", "New Data on Biogen/Elan's Tysabri - Analyst Blog", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "Theravance Inks Deal for Vibativ - Analyst Blog", "AmSurg Maintained at Neutral - Analyst Blog", "DGX Supports Chronic Kidney Guide - Analyst Blog", "BioLineRx to Initiate HCV Study - Analyst Blog", "Lower Loss at Geron - Analyst Blog", "Affymax to Cut 75% of Workforce - Analyst Blog", "New Data on Biogen/Elan's Tysabri - Analyst Blog", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "Theravance Inks Deal for Vibativ - Analyst Blog", "AmSurg Maintained at Neutral - Analyst Blog", "DGX Supports Chronic Kidney Guide - Analyst Blog", "BioLineRx to Initiate HCV Study - Analyst Blog", "Lower Loss at Geron - Analyst Blog", "Affymax to Cut 75% of Workforce - Analyst Blog", "New Data on Biogen/Elan's Tysabri - Analyst Blog", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "Theravance Inks Deal for Vibativ - Analyst Blog", "AmSurg Maintained at Neutral - Analyst Blog", "DGX Supports Chronic Kidney Guide - Analyst Blog", "BioLineRx to Initiate HCV Study - Analyst Blog", "Lower Loss at Geron - Analyst Blog", "Affymax to Cut 75% of Workforce - Analyst Blog", "New Data on Biogen/Elan's Tysabri - Analyst Blog", "SPPI Acquires Late-Stage Candidate - Analyst Blog", "Thermo Fisher Maintained at Neutral - Analyst Blog", "XOMA Posts Narrower Loss - Analyst Blog", "Threshold Cuts Loss, Misses Sales - Analyst Blog", "Peregrine Reports Narrower Loss - Analyst Blog", "Spectrum Guides Lower 2013 Revenue - Analyst Blog", "Genomic Health Reveals Positive Results - Analyst Blog", "Major Setback for Aeterna Zentaris - Analyst Blog", "PDLI Guides Q1 Royalty Revenue - Analyst Blog", "Update on Elan's Plans - Analyst Blog", "Acorda Presents GGF2 Data - Analyst Blog", "Narrower-Than-Expected Loss at OSIR - Analyst Blog", "Elan to Share Tysabri Proceeds - Analyst Blog", "Takeda and Resolve Join Forces - Analyst Blog", "Biogen Files Hemophilia B Application - Analyst Blog", "Major Setback for Aeterna Zentaris - Analyst Blog", "PDLI Guides Q1 Royalty Revenue - Analyst Blog", "Update on Elan's Plans - Analyst Blog", "Acorda Presents GGF2 Data - Analyst Blog", "Narrower-Than-Expected Loss at OSIR - Analyst Blog", "Elan to Share Tysabri Proceeds - Analyst Blog", "Takeda and Resolve Join Forces - Analyst Blog", "Biogen Files Hemophilia B Application - Analyst Blog"], "Elapsed Time": ["JUN 18, 2020", "MAY 13, 2020", "MAY 11, 2020", "MAY 11, 2020", "MAY 8, 2020", "MAY 8, 2020", "MAY 8, 2020", "MAY 7, 2020", "JUN 18, 2020", "APR 30, 2020", "MAR 4, 2020", "FEB 24, 2020", "NOV 27, 2019", "NOV 7, 2019", "NOV 1, 2019", "AUG 9, 2019", "MAY 5, 2020", "MAY 15, 2019", "MAY 9, 2019", "MAR 20, 2019", "FEB 22, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 14, 2019", "AUG 5, 2019", "FEB 13, 2019", "NOV 20, 2018", "NOV 1, 2018", "JUN 18, 2018", "JUN 18, 2018", "JUN 18, 2018", "FEB 18, 2018", "FEB 14, 2019", "NOV 30, 2017", "NOV 22, 2017", "NOV 21, 2017", "NOV 17, 2017", "NOV 1, 2017", "OCT 9, 2017", "OCT 2, 2017", "DEC 12, 2017", "MAY 4, 2017", "APR 21, 2017", "APR 18, 2017", "MAR 8, 2017", "FEB 20, 2017", "FEB 17, 2017", "FEB 17, 2017", "SEP 15, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 14, 2017", "DEC 30, 2016", "DEC 29, 2016", "DEC 29, 2016", "DEC 29, 2016", "FEB 15, 2017", "DEC 22, 2016", "DEC 18, 2016", "NOV 14, 2016", "NOV 8, 2016", "NOV 7, 2016", "OCT 31, 2016", "OCT 28, 2016", "DEC 28, 2016", "SEP 1, 2016", "SEP 1, 2016", "SEP 1, 2016", "SEP 1, 2016", "AUG 30, 2016", "AUG 18, 2016", "AUG 4, 2016", "SEP 23, 2016", "FEB 15, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 12, 2016", "FEB 8, 2016", "FEB 8, 2016", "FEB 5, 2016", "JUN 16, 2016", "FEB 2, 2016", "FEB 2, 2016", "FEB 1, 2016", "FEB 1, 2016", "JAN 29, 2016", "JAN 29, 2016", "JAN 27, 2016", "FEB 3, 2016", "JAN 25, 2016", "JAN 18, 2016", "JAN 15, 2016", "DEC 24, 2015", "DEC 15, 2015", "DEC 4, 2015", "DEC 3, 2015", "JAN 26, 2016", "JAN 25, 2016", "JAN 18, 2016", "JAN 15, 2016", "DEC 24, 2015", "NOV 11, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 23, 2015", "NOV 2, 2015", "NOV 2, 2015", "OCT 30, 2015", "OCT 29, 2015", "AUG 31, 2015", "JUL 24, 2015", "JUL 23, 2015", "NOV 2, 2015", "JUL 15, 2015", "JUL 15, 2015", "JUL 14, 2015", "JUL 14, 2015", "JUN 19, 2015", "APR 17, 2015", "APR 17, 2015", "JUL 23, 2015", "JUL 15, 2015", "JUL 15, 2015", "APR 13, 2015", "APR 13, 2015", "APR 13, 2015", "APR 13, 2015", "APR 16, 2015", "APR 10, 2015", "APR 9, 2015", "APR 9, 2015", "APR 9, 2015", "APR 8, 2015", "APR 8, 2015", "APR 8, 2015", "APR 13, 2015", "APR 10, 2015", "APR 9, 2015", "APR 9, 2015", "APR 9, 2015", "APR 8, 2015", "APR 8, 2015", "APR 8, 2015", "APR 13, 2015", "APR 10, 2015", "APR 9, 2015", "APR 9, 2015", "APR 9, 2015", "APR 8, 2015", "APR 8, 2015", "APR 8, 2015", "APR 13, 2015", "APR 10, 2015", "APR 9, 2015", "APR 9, 2015", "APR 9, 2015", "APR 8, 2015", "APR 8, 2015", "APR 1, 2015", "APR 8, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 31, 2015", "MAR 30, 2015", "MAR 30, 2015", "MAR 27, 2015", "MAR 27, 2015", "MAR 31, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 24, 2015", "MAR 24, 2015", "MAR 23, 2015", "MAR 27, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 26, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 19, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 17, 2015", "MAR 17, 2015", "MAR 19, 2015", "MAR 19, 2015", "MAR 19, 2015", "MAR 19, 2015", "MAR 18, 2015", "MAR 18, 2015", "MAR 17, 2015", "MAR 17, 2015", "MAR 19, 2015", "MAR 16, 2015", "MAR 16, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 12, 2015", "MAR 12, 2015", "MAR 16, 2015", "MAR 6, 2015", "MAR 6, 2015", "MAR 6, 2015", "MAR 5, 2015", "MAR 4, 2015", "MAR 4, 2015", "MAR 3, 2015", "MAR 6, 2015", "MAR 6, 2015", "MAR 6, 2015", "MAR 6, 2015", "MAR 5, 2015", "MAR 4, 2015", "MAR 4, 2015", "MAR 3, 2015", "MAR 6, 2015", "MAR 3, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "FEB 28, 2015", "MAR 3, 2015", "FEB 27, 2015", "FEB 27, 2015", "FEB 26, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 27, 2015", "FEB 23, 2015", "FEB 20, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 18, 2015", "FEB 18, 2015", "FEB 25, 2015", "FEB 13, 2015", "FEB 13, 2015", "JAN 20, 2015", "JAN 2, 2015", "DEC 31, 2014", "DEC 31, 2014", "DEC 29, 2014", "FEB 17, 2015", "DEC 24, 2014", "DEC 24, 2014", "DEC 24, 2014", "NOV 27, 2014", "NOV 25, 2014", "NOV 21, 2014", "NOV 13, 2014", "DEC 5, 2014", "AUG 6, 2014", "AUG 5, 2014", "JUL 14, 2014", "JUN 2, 2014", "JUN 2, 2014", "APR 28, 2014", "APR 25, 2014", "AUG 7, 2014", "APR 25, 2014", "APR 22, 2014", "APR 9, 2014", "APR 9, 2014", "FEB 10, 2014", "FEB 10, 2014", "FEB 7, 2014", "APR 25, 2014", "APR 25, 2014", "OCT 8, 2013", "SEP 5, 2013", "AUG 28, 2013", "AUG 26, 2013", "AUG 23, 2013", "FEB 7, 2014", "AUG 22, 2013", "AUG 8, 2013", "AUG 7, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUN 26, 2013", "JUN 24, 2013", "AUG 22, 2013", "APR 9, 2013", "APR 8, 2013", "APR 8, 2013", "APR 5, 2013", "APR 5, 2013", "APR 5, 2013", "APR 5, 2013", "JUN 18, 2013", "APR 4, 2013", "APR 4, 2013", "APR 4, 2013", "APR 3, 2013", "APR 3, 2013", "APR 3, 2013", "APR 2, 2013", "APR 4, 2013", "APR 4, 2013", "APR 4, 2013", "APR 1, 2013", "APR 1, 2013", "MAR 28, 2013", "MAR 28, 2013", "MAR 28, 2013", "APR 2, 2013", "MAR 28, 2013", "MAR 28, 2013", "MAR 28, 2013", "MAR 27, 2013", "MAR 26, 2013", "MAR 26, 2013", "MAR 26, 2013", "MAR 28, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 22, 2013", "MAR 22, 2013", "MAR 26, 2013", "MAR 22, 2013", "MAR 22, 2013", "MAR 21, 2013", "MAR 21, 2013", "MAR 21, 2013", "MAR 19, 2013", "MAR 19, 2013", "MAR 22, 2013", "MAR 19, 2013", "MAR 18, 2013", "MAR 18, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 14, 2013", "MAR 19, 2013", "MAR 19, 2013", "MAR 18, 2013", "MAR 18, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 14, 2013", "MAR 19, 2013", "MAR 19, 2013", "MAR 18, 2013", "MAR 18, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 15, 2013", "MAR 14, 2013", "MAR 19, 2013", "MAR 19, 2013", "MAR 18, 2013", "MAR 14, 2013", "MAR 14, 2013", "MAR 13, 2013", "MAR 13, 2013", "MAR 13, 2013", "MAR 14, 2013", "MAR 12, 2013", "MAR 12, 2013", "MAR 11, 2013", "MAR 8, 2013", "MAR 7, 2013", "MAR 7, 2013", "MAR 7, 2013", "MAR 13, 2013", "MAR 12, 2013", "MAR 12, 2013", "MAR 11, 2013", "MAR 8, 2013", "MAR 7, 2013", "MAR 7, 2013", "MAR 7, 2013", "MAR 13, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/is-amgen-stock-a-buy-2020-06-18", "https://www.nasdaq.com/articles/is-now-still-a-good-time-to-buy-amgen-2020-05-13", "https://www.nasdaq.com/articles/heres-why-cytokinetics-is-skyrocketing-24.5-today-2020-05-11", "https://www.nasdaq.com/articles/mondays-etf-movers%3A-xbi-kre-2020-05-11", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-banks-boeing-uber-disney-2020-05-08", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-banks-uber-roku-sorrento-therapeutics-2020-05-08", "https://www.nasdaq.com/articles/amgen%3Afda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure-2020-05-08", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q1-2020-earnings-call-transcript-2020-05-07", "https://www.nasdaq.com/articles/is-amgen-stock-a-buy-2020-06-18", "https://www.nasdaq.com/articles/3-monster-growth-stocks-with-still-plenty-of-gas-in-the-tank-2020-04-30", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q4-2019-earnings-call-transcript-2020-03-04", "https://www.nasdaq.com/articles/stock-to-watch%3A-one-down-one-to-go-for-cytokinetics-cytk-2020-02-24", "https://www.nasdaq.com/articles/5-strong-buy-biotech-stocks-with-more-than-80-upside-2019-11-27", "https://www.nasdaq.com/articles/heres-why-cytokinetics-stock-tanked-on-thursday-2019-11-07", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q3-2019-earnings-call-transcript-2019-11-01", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q2-2019-earnings-call-transcript-2019-08-09", "https://www.nasdaq.com/articles/3-biotech-stocks-with-plenty-of-upside-in-the-pipeline-2020-05-05", "https://www.nasdaq.com/articles/analysts-anticipate-16-gains-ahead-ijs-2019-05-15", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q1-2019-earnings-call-transcript-2019-05-10", "https://www.nasdaq.com/articles/heres-why-cytokinetics-stock-jumped-today-2019-03-20", "https://www.nasdaq.com/articles/amgen-starts-phase-iii-enrollment-for-heart-failure-drug-2019-02-22", "https://www.nasdaq.com/articles/cytokinetics-inc-cytk-q4-2018-earnings-conference-call-transcript-2019-02-21", "https://www.nasdaq.com/articles/cytokinetics-cytk-reports-q4-loss-tops-revenue-estimates-2019-02-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biodelivery-cytokinetics-celldex-aduro-and-aeterna-2019", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-wday-cytk-aray-2019-08-05", "https://www.nasdaq.com/articles/5-tiny-biotech-stocks-superb-growth-potential-2019-02-13", "https://www.nasdaq.com/articles/cytokinetics-sees-hammer-chart-pattern%3A-time-to-buy-2018-11-20", "https://www.nasdaq.com/articles/cytokinetics-cytk-reports-q3-loss-tops-revenue-estimates-2018-11-01", "https://www.nasdaq.com/articles/mid-day-market-update-verastem-shares-climb-duvelisib-data-ziopharm-oncology-shares-slide", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-vintage-capital-acquire-rent-center-15share", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-over-1-gevo-shares-spike-higher-2018-06-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-kenneth-fisher-2182018-2018-02-18", "https://www.nasdaq.com/articles/will-cytokinetics-cytk-report-negative-earnings-next-week-what-you-should-know-2019-02-14", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-ilf-2017-11-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-rare-drug-gets-fda-nod-acorda-cytokinetics-hit-pipeline-setbacks", "https://www.nasdaq.com/articles/pre-market-most-active-nov-21-2017-qd-xnet-urbn-sig-cytk-low-tvix-aks-dltr-baba-mt-mu-2017", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-cytokinetics-cytk-stock-2017-11-17", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-sgen-cytk-wrd-2017-11-01", "https://www.nasdaq.com/articles/implied-volatility-surging-for-cytokinetics-cytk-stock-options-2017-10-09", "https://www.nasdaq.com/articles/notable-monday-option-activity-gs-cytk-cmpr-2017-10-02", "https://www.nasdaq.com/articles/paratek-pharmaceuticals-set-explode-holy-grail-antibiotics-omadacycline-nears-fda-approval", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-may-4th-2017-05-04", "https://www.nasdaq.com/articles/after-hours-most-active-apr-21-2017-sbgl-cbl-bac-qqq-msk-vnqi-pey-fb-cytk-trip-nycba-ge", "https://www.nasdaq.com/articles/why-cytokinetics-inc-jumped-higher-today-2017-04-18", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-xop-2017-03-08", "https://www.nasdaq.com/articles/immunogen-posts-wider-than-expected-loss-sales-down-y-y-2017-02-20", "https://www.nasdaq.com/articles/agios-pharma-agio-q4-loss-narrower-than-expected-stock-up-2017-02-17", "https://www.nasdaq.com/articles/kura-oncology-kura-catches-eye%3A-stock-jumps-6.8-2017-02-17", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-cytokinetics-cytk-stock-2017-09-15", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-milacron-holdings-rice-midstream-partners-calavo-growers", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-gilead-sciences-gild-2017-02-15", "https://www.nasdaq.com/articles/5-profitability-stocks-to-make-the-most-of-trump-bump-2017-02-14", "https://www.nasdaq.com/articles/3-reasons-why-cytokinetics-cytk-is-a-great-momentum-stock-2016-12-30", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-calavo-growers-cytokinetics-sucampo-pharmaceuticals-state", "https://www.nasdaq.com/articles/cytokinetics-cytk%3A-an-off-the-radar-potential-winner-2016-12-29", "https://www.nasdaq.com/articles/what-took-so-long-2016-12-29", "https://www.nasdaq.com/articles/acorda-acor-reports-narrower-than-expected-loss-in-q4-2017-02-15", "https://www.nasdaq.com/articles/cytokinetics-cytk%3A-strong-industry-solid-earnings-estimate-revisions-2016-12-22", "https://www.nasdaq.com/articles/3-small-biotech-stocks-big-biotechs-2016-12-18", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-cytokinetics-cytk-2016-11-14", "https://www.nasdaq.com/articles/spinal-muscular-atrophy-focus-biogen-ions-shoot-data-2016-11-08", "https://www.nasdaq.com/articles/cytokinetics-cytk%3A-an-off-the-radar-potential-winner-2016-11-07", "https://www.nasdaq.com/articles/cytokinetics-cytk-worth-watching%3A-stock-surges-10.3-2016-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10282016-cytkatrcopxa-2016-10-28", "https://www.nasdaq.com/articles/5-profitable-stocks-to-buy-for-great-returns-2016-12-28", "https://www.nasdaq.com/articles/health-care-sector-update-09012016-casccynacthtocytk-2016-09-01", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-sgms-cytk-gco-2016-09-01", "https://www.nasdaq.com/articles/why-cytokinetics-inc-got-hammered-today-2016-09-01", "https://www.nasdaq.com/articles/energy-sector-update-09012016-nurocynacthtocytk-2016-09-01", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-cytokinetics-cytk-stock-2016-08-30", "https://www.nasdaq.com/articles/cytokinetics-amyotrophic-lateral-sclerosis-study-enrolled-2016-08-18", "https://www.nasdaq.com/articles/cytokinetics-cytk-shares-march-higher-can-it-continue-2016-08-04", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-cnp-cat-cytk-2016-09-23", "https://www.nasdaq.com/articles/whats-in-store-for-transunions-tru-q4-earnings-2016-02-15", "https://www.nasdaq.com/articles/baxalta-bxlt-to-report-q4-earnings%3A-a-surprise-in-store-2016-02-12", "https://www.nasdaq.com/articles/should-you-buy-cytokinetics-cytk-ahead-of-earnings-2016-02-12", "https://www.nasdaq.com/articles/can-zoetis-zts-keep-the-earnings-streak-alive-in-q4-2016-02-12", "https://www.nasdaq.com/articles/mylan-myl-to-report-q4-earnings%3A-whats-in-the-cards-2016-02-08", "https://www.nasdaq.com/articles/3-biotech-stocks-to-turn-the-tide-this-earnings-season-2016-02-08", "https://www.nasdaq.com/articles/regeneron-regn-to-report-q4-earnings%3A-whats-in-store-2016-02-05", "https://www.nasdaq.com/articles/cytokinetics-cytk-looks-good%3A-stock-adds-6.8-in-session-2016-06-16", "https://www.nasdaq.com/articles/top-rated-stock-picks-and-most-read-stories-nasdaqcom-january-24-30-2016-02-02", "https://www.nasdaq.com/articles/can-perrigo-prgo-beat-q4-earnings-on-generic-sales-2016-02-02", "https://www.nasdaq.com/articles/is-alexion-alxn-likely-to-disappoint-this-earnings-season-2016-02-01", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph%3A-what-awaits-in-q1-earnings-2016-02-01", "https://www.nasdaq.com/articles/whats-in-store-for-nivalis-nvls-this-earnings-season-2016-01-29", "https://www.nasdaq.com/articles/can-gilead-gild-keep-the-earnings-streak-alive-in-q4-2016-01-29", "https://www.nasdaq.com/articles/immunogen-imgn-q2-earnings-preview%3A-what-to-expect-2016-01-27", "https://www.nasdaq.com/articles/will-amerisourcebergens-abc-q1-earnings-disappoint-2016-02-03", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-beat-q4-earnings-expectations-2016-01-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-cytokinetics-and-bristol-myers", "https://www.nasdaq.com/articles/4-biotech-stocks-looking-good-this-earnings-season-2016-01-15", "https://www.nasdaq.com/articles/how-cytokinetics-cytk-stock-stands-out-in-a-strong-industry-2015-12-24", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-december-15th-2015-12-15", "https://www.nasdaq.com/articles/3-most-important-drugs-amgens-pipeline-2015-12-04", "https://www.nasdaq.com/articles/cytokinetics-cytk-looks-good%3A-stock-moves-8.8-higher-2015-12-03", "https://www.nasdaq.com/articles/celgene-celg-to-report-q4-earnings%3A-what-to-expect-2016-01-26", "https://www.nasdaq.com/articles/will-bristol-myers-bmy-beat-q4-earnings-expectations-2016-01-25", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-biogen-cytokinetics-and-bristol-myers", "https://www.nasdaq.com/articles/4-biotech-stocks-looking-good-this-earnings-season-2016-01-15", "https://www.nasdaq.com/articles/how-cytokinetics-cytk-stock-stands-out-in-a-strong-industry-2015-12-24", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-angies-list-athenahealth-cytokinetics-meetme", "https://www.nasdaq.com/articles/intercept-icpt-posts-narrower-than-expected-loss-in-q3-2015-11-10", "https://www.nasdaq.com/articles/5-stocks-rocketing-new-highs-2015-11-10", "https://www.nasdaq.com/articles/can-cytokinetics-cytk-run-higher-on-strong-earnings-estimate-revisions-2015-11-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-surges-150-points-lendingtree-shares-slide-2015-11-02", "https://www.nasdaq.com/articles/monday-sector-leaders-biotechnology-drugs-2015-11-02", "https://www.nasdaq.com/articles/cytokinetics-cytk-jumps%3A-stock-adds-16.6-in-session-2015-10-30", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-mnkd-vtl-cytk-2015-10-29", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-cytokinetics-cytk%3A-time-to-buy-2015-08-31", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-24th-tale-of-the-tape-2015-07-24", "https://www.nasdaq.com/articles/will-biogen-biib-surprise-in-2q-despite-tecfidera-issues-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/mid-day-market-update-dyax-jumps-acquisition-news-endurance-international-shares-dip-2015", "https://www.nasdaq.com/articles/cytokinetics-cytk-jumps%3A-stock-adds-6.8-in-session-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/cytokinetics-advances-tirasemtiv-to-phase-iii-shares-up-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/mid-day-market-update-vince-holding-declines-after-ceo-resignation-natural-health-trends", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rise-jpmorgan-earnings-beat-views-2015-07-14", "https://www.nasdaq.com/articles/health-care-sector-update-06192015-achc-bmrn-cytk-2015-06-19", "https://www.nasdaq.com/articles/targacepts-diabetic-gastroparesis-drug-fails-to-impress-analyst-blog-2015-04-17", "https://www.nasdaq.com/articles/targacepts-diabetic-gastroparesis-drug-fails-to-impress-analyst-blog-2015-04-17-0", "https://www.nasdaq.com/articles/will-abbvie-abbv-surprise-earnings-again-q2-analyst-blog-2015-07-23", "https://www.nasdaq.com/articles/cytokinetics-cytk-jumps%3A-stock-adds-6.8-in-session-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/cytokinetics-advances-tirasemtiv-to-phase-iii-shares-up-analyst-blog-2015-07-15", "https://www.nasdaq.com/articles/alexion-up-as-soliris-gains-eu-nod-for-label-updates-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/astrazenecas-onglyza-briefing-documents-raise-concern-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/amgen-upgraded-to-strong-buy-perfect-for-your-portfolio-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/adamas-pharmas-lead-candidate-gets-orphan-status-in-u.s.-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/celsion-gains-on-impressive-breast-cancer-study-data-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/the-medicines-co.-posts-disappointing-preliminary-results-analyst-blog-2015-04-10", "https://www.nasdaq.com/articles/oncolytics-reolysin-filed-for-gastric-cancer-orphan-status-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/halozyme-to-advance-pegph20-following-fda-meet-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-ndas-under-fda-review-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/merck-kgaa-pfizer-to-co-promote-xalkori-for-lung-cancer-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/arena-pharmaceuticals-up-on-belviqs-new-patent-approval-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/horizon-pharmas-actimmune-gets-fast-track-status-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/the-medicines-co.-posts-disappointing-preliminary-results-analyst-blog-2015-04-10", "https://www.nasdaq.com/articles/oncolytics-reolysin-filed-for-gastric-cancer-orphan-status-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/halozyme-to-advance-pegph20-following-fda-meet-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-ndas-under-fda-review-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/merck-kgaa-pfizer-to-co-promote-xalkori-for-lung-cancer-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/arena-pharmaceuticals-up-on-belviqs-new-patent-approval-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/horizon-pharmas-actimmune-gets-fast-track-status-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/the-medicines-co.-posts-disappointing-preliminary-results-analyst-blog-2015-04-10", "https://www.nasdaq.com/articles/oncolytics-reolysin-filed-for-gastric-cancer-orphan-status-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/halozyme-to-advance-pegph20-following-fda-meet-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-ndas-under-fda-review-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/merck-kgaa-pfizer-to-co-promote-xalkori-for-lung-cancer-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/arena-pharmaceuticals-up-on-belviqs-new-patent-approval-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/horizon-pharmas-actimmune-gets-fast-track-status-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/the-medicines-co.-posts-disappointing-preliminary-results-analyst-blog-2015-04-10", "https://www.nasdaq.com/articles/oncolytics-reolysin-filed-for-gastric-cancer-orphan-status-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/halozyme-to-advance-pegph20-following-fda-meet-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-ndas-under-fda-review-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/merck-kgaa-pfizer-to-co-promote-xalkori-for-lung-cancer-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/gilead-submits-regulatory-application-for-hiv-drug-in-u.s.-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/dyaxs-hereditary-angioedema-drug-meets-primary-endpoint-analyst-blog-2015-04-01", "https://www.nasdaq.com/articles/ocular-therapeutix-slumps-19-after-negative-study-data-analyst-blog-2015-04-08", "https://www.nasdaq.com/articles/horizon-pharma-to-buy-hyperion-therapeutics-for-%241.1b-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/intrexon-merck-kgaa-team-up-for-car-t-cancer-therapies-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/amgens-kyprolis-gets-fda-priority-review-for-expanded-use-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/heat-biologics-posts-wider-loss-y-y-focus-on-pipeline-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/proteon-up-on-positive-long-term-data-on-its-candidate-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/novo-nordisk-to-submit-interim-devote-data-to-the-fda-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/conatus-soars-on-positive-phase-ii-data-on-emricasan-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/the-medicines-co.s-3-acute-care-drugs-approved-in-eu-analyst-blog-2015-03-31", "https://www.nasdaq.com/articles/novo-nordisks-onset-1-onset-2-meet-primary-objectives-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/sanofi-reveals-cerdelga-data-fda-oks-quadracel-vaccine-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/oncolytics-cancer-drug-reolysin-gets-orphan-status-in-eu-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/medivation-astellas-xtandi-positive-in-prostate-cancer-study-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/vertex-falls-on-disappointing-kalydecovx-661-combo-data-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/novo-nordisks-saxenda-gets-eu-approval-for-obesity-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/eli-lilly-partners-with-innovent-to-develop-oncology-drugs-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/immune-design-starts-dosing-patients-in-cmb305-study-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/novo-nordisks-onset-1-onset-2-meet-primary-objectives-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/sanofi-reveals-cerdelga-data-fda-oks-quadracel-vaccine-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/oncolytics-cancer-drug-reolysin-gets-orphan-status-in-eu-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/sanofi-inks-multi-component-strategic-deal-with-evotec-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/eli-lilly-collaborates-with-korean-hanmi-pharmaceutical-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/theravance-glaxos-breo-ellipta-gets-mixed-fda-panel-view-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/juno-therapeutics-juno-q4-loss-wider-than-expected-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/celgene-presents-efficacy-safety-data-on-otezla-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/pfizer-reveals-detailed-xeljanz-data-from-psoriasis-study-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/prothenas-prx002-positive-in-parkinsons-disease-study-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/coronado-biosciences-jumps-on-agreement-with-neupharma-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/sanofi-inks-multi-component-strategic-deal-with-evotec-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/ruthigen-pulmatrix-merge-focus-on-respiratory-drugs-analyst-blog-2015-03-17", "https://www.nasdaq.com/articles/acelrx-starts-pivotal-study-on-acute-pain-management-drug-analyst-blog-2015-03-17", "https://www.nasdaq.com/articles/celgenes-data-on-crohns-disease-candidate-published-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/vertexs-kalydeco-gets-fda-nod-for-additional-indication-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/retrophin-soars-on-fda-approval-of-bile-acid-disorder-drug-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/lexicon-ipsen-agreement-expanded-to-include-canada-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/nektars-breast-cancer-candidate-fails-in-beacon-study-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/kite-pharma-kite-acquires-t-cell-factory-focus-on-europe-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/ruthigen-pulmatrix-merge-focus-on-respiratory-drugs-analyst-blog-2015-03-17", "https://www.nasdaq.com/articles/acelrx-starts-pivotal-study-on-acute-pain-management-drug-analyst-blog-2015-03-17", "https://www.nasdaq.com/articles/celgenes-data-on-crohns-disease-candidate-published-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/mercks-sugammadex-faces-setback-fda-delays-meeting-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/alnylam-announces-positive-data-from-natural-history-study-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/epizymes-loss-narrower-than-expected-focus-on-pipeline-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/syntas-q4-loss-narrows-y-y-focus-on-lung-cancer-drug-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/bristol-myers-seeks-daclatasvir-approval-in-the-u.s.-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/xoma-reports-narrower-y-y-loss-in-q4-misses-on-revs-analyst-blog-2015-03-12", "https://www.nasdaq.com/articles/sciclone-scln-beats-on-q4-earnings-gives-2015-outlook-analyst-blog-2015-03-12", "https://www.nasdaq.com/articles/actelions-uptravi-shows-long-term-benefit-in-griphon-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/emergent-biosolutions-lags-earnings-cancels-2015-view-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/tg-therapeutics-coronado-sign-up-immuno-oncology-deal-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/bristol-myers-oncology-drug-opdivo-label-expanded-in-u.s.-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/shire-submits-nda-for-dry-eye-disease-drug-lifitegrast-analyst-blog-2015-03-05", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-up-on-u.s.-approval-of-xyrem-rems-analyst-blog-2015-03-04", "https://www.nasdaq.com/articles/oncolytics-reolysin-gets-orphan-drug-status-yet-again-analyst-blog-2015-03-04", "https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-2015-guidance-encouraging-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/osiris-therapeutics-q4-earnings-down-y-y-revenues-soar-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/emergent-biosolutions-lags-earnings-cancels-2015-view-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/tg-therapeutics-coronado-sign-up-immuno-oncology-deal-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/bristol-myers-oncology-drug-opdivo-label-expanded-in-u.s.-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/shire-submits-nda-for-dry-eye-disease-drug-lifitegrast-analyst-blog-2015-03-05", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-up-on-u.s.-approval-of-xyrem-rems-analyst-blog-2015-03-04", "https://www.nasdaq.com/articles/oncolytics-reolysin-gets-orphan-drug-status-yet-again-analyst-blog-2015-03-04", "https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-2015-guidance-encouraging-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/osiris-therapeutics-q4-earnings-down-y-y-revenues-soar-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/bristol-myers-files-for-new-indications-for-yervoy-opdivo-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/qlt-qlti-reports-wider-year-over-year-loss-in-q4-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/endo-endp-beats-q4-earnings-announces-divestments-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/horizon-pharma-beats-on-q4-earnings-lifts-2015-guidance-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/gileads-gild-hiv-drug-positive-in-2-phase-iii-studies-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/alexions-soliris-label-may-be-updated-upon-ec-approval-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/amgens-kyprolis-under-eu-review-analyst-blog-2015-02-28", "https://www.nasdaq.com/articles/amgen-celimmune-tie-up-for-autoimmune-disorder-drug-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/merrimack-pharmaceuticals-q4-loss-narrower-than-expected-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/aegerions-q4-loss-narrows-y-y-ups-juxtapid-sales-view-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/amgen-reports-encouraging-late-stage-data-on-amg-416-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/nektar-therapeutics-incurs-narrower-than-expected-q4-loss-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/mannkind-reports-narrower-y-y-loss-in-q4-afrezza-in-focus-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/vivus-q4-loss-wider-than-expected-qsymia-disappoints-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/alkermes-falls-on-pipeline-news-q4-earnings-plunge-y-y-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/bayer-q4-net-income-down-y-y-provides-2015-outlook-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/celgene-gains-on-label-expansion-of-revlimid-in-the-eu-analyst-blog-2015-02-23", "https://www.nasdaq.com/articles/celgene-up-on-hematology-drug-revlimids-label-expansion-analyst-blog-2015-02-20", "https://www.nasdaq.com/articles/coronado-biosciences-in-licenses-revogenexs-pain-drug-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/the-medicines-co.-earnings-down-y-y-angiomax-sales-grow-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/seattle-genetics-sgen-filed-supplemental-bla-for-adcetris-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/cytokinetics-cytk-shows-strength%3A-stock-moves-up-5-tale-of-the-tape-2015-02-18", "https://www.nasdaq.com/articles/seattle-genetics-sea-cd40-enters-phase-i-for-solid-tumors-analyst-blog-2015-02-18", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-tops-q4-earnings-provides-guidance-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/why-shares-cytokinetics-incorporated-skyrocketed-2015-02-13", "https://www.nasdaq.com/articles/health-care-sector-update-02132015-2015-02-13", "https://www.nasdaq.com/articles/will-cytokinetics-cytk-continue-to-surge-higher-tale-of-the-tape-2015-01-20", "https://www.nasdaq.com/articles/cytokinetics-cytk-looks-good%3A-stock-soars-16.1-tale-of-the-tape-2015-01-02", "https://www.nasdaq.com/articles/mid-day-market-update-meadowbrook-insurance-shares-jump-acquisition-news-crude-oil-drops", "https://www.nasdaq.com/articles/mid-afternoon-market-update-us-stocks-turn-red-tekmira-pharmaceuticals-shares-climb", "https://www.nasdaq.com/articles/kite-pharma-files-ind-for-non-hodgkin-lymphoma-drug-analyst-blog-2014-12-29", "https://www.nasdaq.com/articles/why-cytokinetics-inc-shares-soared-today-2015-02-17", "https://www.nasdaq.com/articles/cytokinetics-incorporated-cytk-rises%3A-stock-jumps-12.6-tale-of-the-tape-2014-12-24", "https://www.nasdaq.com/articles/cytokinetics-rises-after-extending-astellas-agreement-analyst-blog-2014-12-24", "https://www.nasdaq.com/articles/myriad-genetics-ovarian-cancer-test-wins-fda-approval-analyst-blog-2014-12-24", "https://www.nasdaq.com/articles/avanirs-migraine-drug-gets-complete-response-letter-analyst-blog-2014-11-27", "https://www.nasdaq.com/articles/amgen-ends-gastric-cancer-drug-studies-safety-review-analyst-blog-2014-11-25", "https://www.nasdaq.com/articles/epizyme-gains-on-positive-phase-i-data-on-epz-6438-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/3-stocks-buy-your-bull-market-profits-2014-11-13", "https://www.nasdaq.com/articles/health-care-sector-update-12052014-cytkatospbmd-2014-12-05", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-inc.-snss-jumps%3A-stock-rises-9-tale-of-the-tape-2014-08-06", "https://www.nasdaq.com/articles/amgens-multiple-myeloma-drug-kyprolis-succeeds-analyst-blog-2014-08-05", "https://www.nasdaq.com/articles/cytokinetics-up-on-positive-tirasemtiv-data-analyst-blog-2014-07-14", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-immunocelluar-12-positive-data", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-02", "https://www.nasdaq.com/articles/cytokinetics-tirasemtiv-misses-primary-endpoint-analyst-blog-2014-04-28", "https://www.nasdaq.com/articles/late-slump-erodes-healthcare-sector-cytokinetics-loses-nearly-two-thirds-value-after-als", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q2-earnings-revenues-shares-up-analyst-blog-2014-08-07", "https://www.nasdaq.com/articles/friday-sector-laggards-biotechnology-construction-materials-machinery-stocks-2014-04-25", "https://www.nasdaq.com/articles/cytokinetics-incorporated-cytk-jumps%3A-stock-up-13.5-tale-of-the-tape-2014-04-22", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-post-large-rally-intuitive-surgical-shares-remain-down", "https://www.nasdaq.com/articles/mid-day-market-update-alcoa-surges-upbeat-earnings-intuitive-surgical-shares-slip-2014-04", "https://www.nasdaq.com/articles/cytokinetics-rises-on-q4-earnings-beat-analyst-blog-2014-02-10", "https://www.nasdaq.com/articles/cytokinetics-incorporated-cytk-soars%3A-stock-up-26-in-session-tale-of-the-tape-2014-02-10", "https://www.nasdaq.com/articles/robust-gains-healthcare-stocks-cytokinetics-soars-after-surprise-q4-profit-11-fold-jump", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-25", "https://www.nasdaq.com/articles/friday-sector-laggards-biotechnology-construction-materials-machinery-stocks-2014-04-25", "https://www.nasdaq.com/articles/cytokinetics-inc.-enters-oversold-territory-tale-of-the-tape-2013-10-08", "https://www.nasdaq.com/articles/amgen-cytokinetics-drug-misses-primary-endpoint-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/amgen-to-present-data-at-esc-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/cytokinetics-previewing-release-data-atomic-ahf-trial-omecamtiv-mecarbil-2013-08-26", "https://www.nasdaq.com/articles/cytokinetics-tirasemtiv-data-published-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-07", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-08-22", "https://www.nasdaq.com/articles/loss-narrows-at-idenix-in-q2-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/cytokinetics-preview-key-upcoming-clinical-trial-results-2013-08-07", "https://www.nasdaq.com/articles/amgen-servier-ink-deal-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/cytokinetics-update-on-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/cytokinetics-astellas-collaborate-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/theravances-vibativ-expanded-in-the-us-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/healthcare-stocks-slightly-higher-afternoon-cytokinetics-advances-after-new-data-find-als", "https://www.nasdaq.com/articles/patients-dosed-in-arena-study-analyst-blog-2013-04-09", "https://www.nasdaq.com/articles/azn-reports-data-on-fostamatinib-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/data-presented-on-bayers-atx-101-analyst-blog-2013-04-08", "https://www.nasdaq.com/articles/cytokinetics-begins-ck-2127107-study-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/ghdx-to-show-prostate-test-result-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/glaxo-eyes-benlysta-label-expansion-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/qlt-sells-ppds-technology-analyst-blog-2013-04-05", "https://www.nasdaq.com/articles/market-wrap-tuesday-june-18-stocks-rally-ahead-fed-statement-2013-06-18", "https://www.nasdaq.com/articles/update-on-protalix-gaucher-study-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/astrazeneca-takes-over-alphacore-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/orphan-status-for-insmeds-arikace-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/biomarin-files-cta-for-bmn-190-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/arna-eisais-belviq-filed-in-mexico-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/elan-sells-off-tysabri-stake-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/celgene-reaches-52-week-high-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/elan-gets-takeover-clarity-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/update-on-protalix-gaucher-study-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/astrazeneca-takes-over-alphacore-analyst-blog-2013-04-04", "https://www.nasdaq.com/articles/gileads-hcv-study-to-continue-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/bad-news-for-alexion-shares-down-analyst-blog-2013-04-01", "https://www.nasdaq.com/articles/omeros-progresses-with-oms824-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/takeda-seeks-japanese-approval-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/balanced-view-on-gilead-sciences-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/vivus-opts-for-royalty-financing-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/labcorp-remains-at-neutral-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/life-explores-chinas-growth-potential-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/affymetrix-inks-deal-with-uk-biobank-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/takeda-files-adcetris-in-japan-analyst-blog-2013-03-27", "https://www.nasdaq.com/articles/chmp-negative-on-gentium-candidate-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/acorda-reports-data-on-epilepsy-drug-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/integras-second-cobalt-chrome-rod-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/setback-for-idenix-pharma-analyst-blog-2013-03-28", "https://www.nasdaq.com/articles/chmp-positive-on-biogens-tecfidera-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/cytokinetics-critical-phase-iib-data-upcoming-2013-omecamtiv-mecarbil-and-tirasemtiv-2013", "https://www.nasdaq.com/articles/chmp-positive-on-ariads-iclusig-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/chmp-still-negative-on-isis-kynamro-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/pipeline-setback-at-biolinerx-analyst-blog-2013-03-25", "https://www.nasdaq.com/articles/more-protection-for-biogens-tecfidera-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/fda-nod-for-integras-extremity-offer-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/zimmer-optimistic-about-new-product-analyst-blog-2013-03-26", "https://www.nasdaq.com/articles/petmed-reiterated-at-outperform-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/zimmer-expands-knee-product-offering-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/data-on-biomarins-bmn-701-analyst-blog-2013-03-21", "https://www.nasdaq.com/articles/good-news-for-nymoxs-pipeline-analyst-blog-2013-03-21", "https://www.nasdaq.com/articles/isis-presents-promising-data-analyst-blog-2013-03-21", "https://www.nasdaq.com/articles/sgen-seeks-adcetris-label-expansion-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/dgx-to-launch-dementia-test-panel-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/nice-news-for-intermune-analyst-blog-2013-03-22", "https://www.nasdaq.com/articles/new-data-on-biogen-elans-tysabri-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/theravance-inks-deal-for-vibativ-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/amsurg-maintained-at-neutral-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/dgx-supports-chronic-kidney-guide-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/biolinerx-to-initiate-hcv-study-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/lower-loss-at-geron-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/affymax-to-cut-75-of-workforce-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/new-data-on-biogen-elans-tysabri-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/theravance-inks-deal-for-vibativ-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/amsurg-maintained-at-neutral-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/dgx-supports-chronic-kidney-guide-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/biolinerx-to-initiate-hcv-study-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/lower-loss-at-geron-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/affymax-to-cut-75-of-workforce-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/new-data-on-biogen-elans-tysabri-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/theravance-inks-deal-for-vibativ-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/amsurg-maintained-at-neutral-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/dgx-supports-chronic-kidney-guide-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/biolinerx-to-initiate-hcv-study-analyst-blog-2013-03-15", "https://www.nasdaq.com/articles/lower-loss-at-geron-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/affymax-to-cut-75-of-workforce-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/new-data-on-biogen-elans-tysabri-analyst-blog-2013-03-19", "https://www.nasdaq.com/articles/sppi-acquires-late-stage-candidate-analyst-blog-2013-03-18", "https://www.nasdaq.com/articles/thermo-fisher-maintained-at-neutral-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/xoma-posts-narrower-loss-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/threshold-cuts-loss-misses-sales-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/peregrine-reports-narrower-loss-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/spectrum-guides-lower-2013-revenue-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/genomic-health-reveals-positive-results-analyst-blog-2013-03-14", "https://www.nasdaq.com/articles/major-setback-for-aeterna-zentaris-analyst-blog-2013-03-12", "https://www.nasdaq.com/articles/pdli-guides-q1-royalty-revenue-analyst-blog-2013-03-12", "https://www.nasdaq.com/articles/update-on-elans-plans-analyst-blog-2013-03-11", "https://www.nasdaq.com/articles/acorda-presents-ggf2-data-analyst-blog-2013-03-08", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-osir-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/elan-to-share-tysabri-proceeds-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/takeda-and-resolve-join-forces-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/biogen-files-hemophilia-b-application-analyst-blog-2013-03-13", "https://www.nasdaq.com/articles/major-setback-for-aeterna-zentaris-analyst-blog-2013-03-12", "https://www.nasdaq.com/articles/pdli-guides-q1-royalty-revenue-analyst-blog-2013-03-12", "https://www.nasdaq.com/articles/update-on-elans-plans-analyst-blog-2013-03-11", "https://www.nasdaq.com/articles/acorda-presents-ggf2-data-analyst-blog-2013-03-08", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-osir-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/elan-to-share-tysabri-proceeds-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/takeda-and-resolve-join-forces-analyst-blog-2013-03-07", "https://www.nasdaq.com/articles/biogen-files-hemophilia-b-application-analyst-blog-2013-03-13"], "Content": []}